Order Article Reprints

Cao H, Tadros V, Hiramoto B, Leeper K, Hino C, Xiao J, Pham B, Kim DH, Reeves ME, Chen C-S, et al. Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability. Biomedicines. 2022; 10(5):1038. https://doi.org/10.3390/biomedicines10051038

Cao, Huynh, Verena Tadros, Benjamin Hiramoto, Kevin Leeper, Christopher Hino, Jeffrey Xiao, Bryan Pham, Do Hyun Kim, Mark E. Reeves, Chien-Shing Chen, and et al. 2022. "Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability" Biomedicines 10, no. 5: 1038. https://doi.org/10.3390/biomedicines10051038

Cao, H., Tadros, V., Hiramoto, B., Leeper, K., Hino, C., Xiao, J., Pham, B., Kim, D. H., Reeves, M. E., Chen, C.-S., Zhong, J. F., Zhang, K. K., Xie, L., Wasnik, S., Baylink, D. J., & Xu, Y. (2022). Targeting TKI-Activated NFKB2-MIF/CXCLs-CXCR2 Signaling Pathways in FLT3 Mutated Acute Myeloid Leukemia Reduced Blast Viability. Biomedicines, 10(5), 1038. https://doi.org/10.3390/biomedicines10051038